Nanotechnology innovation in Point of Care testing - by Marcel van Kasteel, CEO Handheld Diagnostic, page-22

And we have from BBI in Nov 2013 (http://www.biotechdaily.com.au/media/backissues/2013/11 Nov/BD Biotech Daily Nov 8.pdf):

"BBI managing director Fiona Marshall said her company “has been interested in the benefits that may come from the use of Mix&Go in our systems for some time now”. “Our earlier collaborative study has supported an assertion that Mix&Go may become part of our exciting portfolio of nano-particles,” Ms Marshall said."

BBI website:
"Nanoparticle Labels BBI manufactures large volumes of the highest quality colloidal gold and gold nanoparticles conjugated to your antibody of choice. Unique recipe gold colloid has been used for over 20 years due to its superior quality and performance, and features in over 400 million tests in the global market place per year. Many of these have FDA cleared status."

ADO's quarterly:

"To our delight and their surprise we improved sensitivities between 3 and 5 fold and believe that further improvements are possible with additional optimisation. Increases in sensitivity may not have great commercial value for the antibodies tested but if similar improvements are achieved with other antibodies then the commercial ramifications are likely to be significant.

Since we submitted our report to BBI they have undergone some internal restructuring and reassessment of priorities. Recently, we were informed of their decision to proceed to the final phases of the project, including scale - up, outlined in the Heads of Terms. Their management expressed satisfaction with the progress made on the project to date and high expectations for the outcome of the collaboration into the future."

IMO, once the BBI IPO is completed an announcement regarding an improvement in their sensitivity and accuracy or their nanoparticle testing would do wonders for BBI's new share price.  All pure speculation and DYOR and have patience.